| Name | Title | Contact Details |
|---|
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
Aimmune Therapeutics, Inc. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for patients with food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company`s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies. Aimmune is located in Brisbane, California - the heart of San Francisco`s biotechnology hub - with additional offices in the Kings Cross area of London and in Durham, North Carolina.
NeuroVasc Technologies is a developer of mechanical thrombectomy solutions for revascularization of the brain.
Kaiser Inc is a Manteca, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GRACE NETWORK is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.